ABIONYX Pharma Reports Stable Revenue and Cash Position for 2024

ABIONYX Pharma has announced its financial results for the 2024 fiscal year, highlighting a consolidated turnover of €4.6 million. This revenue is primarily attributed to its subsidiary, IRIS Pharma, which maintained consistent performance compared to 2023, despite challenges in the CRO industry. The company's biotech segment, focused on developing innovative therapies, did not generate revenue, as ABIONYX continues to provide its bioproducts free of charge for Compassionate Access Authorization (CAA) requests, particularly for the treatment of the orphan disease LCAT.

At the end of 2024, ABIONYX reported cash and cash equivalents totaling €3.2 million, showing a decrease from €4.1 million at the close of 2023. The company remains committed to its mission of advancing treatments for severe inflammatory diseases, while handling ongoing CAA requests from hospitals worldwide.